Logo image of 1SRPT.MI

SAREPTA THERAPEUTICS INC (1SRPT.MI) Stock Fundamental Analysis

BIT:1SRPT - US8036071004 - Common Stock

15.495 EUR
+0.4 (+2.65%)
Last: 8/29/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to 1SRPT. 1SRPT was compared to 74 industry peers in the Biotechnology industry. Both the profitability and financial health of 1SRPT have multiple concerns. 1SRPT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

1SRPT had negative earnings in the past year.
In the past year 1SRPT has reported a negative cash flow from operations.
In the past 5 years 1SRPT reported 4 times negative net income.
1SRPT had negative operating cash flow in 4 of the past 5 years.
1SRPT.MI Yearly Net Income VS EBIT VS OCF VS FCF1SRPT.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

1SRPT has a better Return On Assets (-1.57%) than 68.92% of its industry peers.
With a decent Return On Equity value of -4.27%, 1SRPT is doing good in the industry, outperforming 70.27% of the companies in the same industry.
Industry RankSector Rank
ROA -1.57%
ROE -4.27%
ROIC N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
1SRPT.MI Yearly ROA, ROE, ROIC1SRPT.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

1SRPT has a Gross Margin of 79.28%. This is in the better half of the industry: 1SRPT outperforms 74.32% of its industry peers.
In the last couple of years the Gross Margin of 1SRPT has remained more or less at the same level.
1SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
1SRPT.MI Yearly Profit, Operating, Gross Margins1SRPT.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

1SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1SRPT has been increased compared to 1 year ago.
Compared to 5 years ago, 1SRPT has more shares outstanding
Compared to 1 year ago, 1SRPT has an improved debt to assets ratio.
1SRPT.MI Yearly Shares Outstanding1SRPT.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
1SRPT.MI Yearly Total Debt VS Total Assets1SRPT.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

1SRPT has an Altman-Z score of 0.00. This is a bad value and indicates that 1SRPT is not financially healthy and even has some risk of bankruptcy.
1SRPT has a Altman-Z score of 0.00. This is comparable to the rest of the industry: 1SRPT outperforms 48.65% of its industry peers.
A Debt/Equity ratio of 0.84 indicates that 1SRPT is somewhat dependend on debt financing.
1SRPT has a Debt to Equity ratio of 0.84. This is comparable to the rest of the industry: 1SRPT outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Altman-Z 0
ROIC/WACCN/A
WACC7.83%
1SRPT.MI Yearly LT Debt VS Equity VS FCF1SRPT.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

1SRPT has a Current Ratio of 2.89. This indicates that 1SRPT is financially healthy and has no problem in meeting its short term obligations.
1SRPT's Current ratio of 2.89 is fine compared to the rest of the industry. 1SRPT outperforms 64.86% of its industry peers.
1SRPT has a Quick Ratio of 1.81. This is a normal value and indicates that 1SRPT is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of 1SRPT (1.81) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.89
Quick Ratio 1.81
1SRPT.MI Yearly Current Assets VS Current Liabilites1SRPT.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

1SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -293.33%.
1SRPT shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.89%.
Measured over the past years, 1SRPT shows a very strong growth in Revenue. The Revenue has been growing by 37.94% on average per year.
EPS 1Y (TTM)-293.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2600%
Revenue 1Y (TTM)64.89%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%68.38%

3.2 Future

The Earnings Per Share is expected to grow by 0.81% on average over the next years.
Based on estimates for the next years, 1SRPT will show a decrease in Revenue. The Revenue will decrease by -6.31% on average per year.
EPS Next Y-282.9%
EPS Next 2Y-16.02%
EPS Next 3Y-7.82%
EPS Next 5Y0.81%
Revenue Next Year3.14%
Revenue Next 2Y-12.67%
Revenue Next 3Y-8.01%
Revenue Next 5Y-6.31%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
1SRPT.MI Yearly Revenue VS Estimates1SRPT.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
1SRPT.MI Yearly EPS VS Estimates1SRPT.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 -4 -6 -8

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

1SRPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 11.22, the valuation of 1SRPT can be described as reasonable.
1SRPT's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1SRPT is cheaper than 91.89% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of 1SRPT to the average of the S&P500 Index (22.52), we can say 1SRPT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 11.22
1SRPT.MI Price Earnings VS Forward Price Earnings1SRPT.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

1SRPT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. 1SRPT is cheaper than 74.32% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 45.42
1SRPT.MI Per share data1SRPT.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

A cheap valuation may be justified as 1SRPT's earnings are expected to decrease with -7.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.02%
EPS Next 3Y-7.82%

More info and screens

0

5. Dividend

5.1 Amount

1SRPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAREPTA THERAPEUTICS INC

BIT:1SRPT (8/29/2025, 7:00:00 PM)

15.495

+0.4 (+2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners96.69%
Inst Owner ChangeN/A
Ins Owners4.4%
Ins Owner ChangeN/A
Market Cap1.52B
Analysts67.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-114.71%
Min EPS beat(2)-376.26%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)24.21%
Min EPS beat(4)-376.26%
Max EPS beat(4)348.76%
EPS beat(8)6
Avg EPS beat(8)617.4%
EPS beat(12)8
Avg EPS beat(12)384.79%
EPS beat(16)10
Avg EPS beat(16)285.72%
Revenue beat(2)2
Avg Revenue beat(2)9.95%
Min Revenue beat(2)6.86%
Max Revenue beat(2)13.04%
Revenue beat(4)4
Avg Revenue beat(4)8.67%
Min Revenue beat(4)2.86%
Max Revenue beat(4)13.04%
Revenue beat(8)7
Avg Revenue beat(8)5.95%
Revenue beat(12)9
Avg Revenue beat(12)3.94%
Revenue beat(16)12
Avg Revenue beat(16)3.6%
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-1428.04%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-30.45%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.68%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.22
P/S 0.71
P/FCF N/A
P/OCF N/A
P/B 1.31
P/tB 1.34
EV/EBITDA 45.42
EPS(TTM)-0.75
EYN/A
EPS(NY)1.38
Fwd EY8.91%
FCF(TTM)-3.97
FCFYN/A
OCF(TTM)-2.63
OCFYN/A
SpS21.68
BVpS11.86
TBVpS11.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.57%
ROE -4.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.28%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score2
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.84
Debt/FCF N/A
Debt/EBITDA 28.38
Cap/Depr 372.98%
Cap/Sales 6.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.89
Quick Ratio 1.81
Altman-Z 0
F-Score2
WACC7.83%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-293.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2600%
EPS Next Y-282.9%
EPS Next 2Y-16.02%
EPS Next 3Y-7.82%
EPS Next 5Y0.81%
Revenue 1Y (TTM)64.89%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%68.38%
Revenue Next Year3.14%
Revenue Next 2Y-12.67%
Revenue Next 3Y-8.01%
Revenue Next 5Y-6.31%
EBIT growth 1Y-102.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-308.31%
EBIT Next 3Y-28%
EBIT Next 5Y-24.41%
FCF growth 1Y15.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.48%
OCF growth 3YN/A
OCF growth 5YN/A